Getting listed: how pharmacy wholesalers evaluate a new product

Brand owners tend to present a new product the way they built it: formulation first, evidence second, commercial terms last. Wholesale and pharmacy buyers read it in the opposite order, and a pitch structured the wrong way round often fails before the product is understood.

A listing decision is a shelf-space allocation decision. The buyer is not asking whether the product is good. They are asking what it displaces.

What is actually assessed

Margin structure through the chain. Not your price — the margin available to the wholesaler and to the pharmacy at the price the consumer will pay. A product that is attractive at manufacturer level and thin at pharmacy level does not get recommended at the counter, and a product that is not recommended does not reorder.

Pack size against the therapy or usage period. A pack that runs out mid-course invites a switch at the repeat; a pack that lasts too long depresses reorder frequency. Both are visible in the buyer’s rotation model before they are visible to you.

Category fit and cannibalisation. If the range already carries three comparable products, the question is which one you replace. An honest answer to that question is a much stronger pitch than claiming to be incomparable.

Master data completeness. Registration number, EAN/GTIN, dimensions, weight, storage conditions, shelf life, VAT rate, pack contents. Incomplete data is the most common reason a listing that was agreed in principle sits unprocessed for a quarter.

Expected rotation, with a reason. Buyers discount unsupported forecasts to near zero. A forecast tied to something concrete — a comparable SKU’s actual rotation, a defined launch support plan, an existing consumer base — is treated differently.

The identifiers, and why they gate everything

In Germany and Austria a product needs a PZN (Pharmazentralnummer) before it can be ordered through pharmacy systems at all. In Switzerland the equivalent role is played by the national article numbering used by pharmacy wholesalers. These are not marketing details; they are the key the entire ordering infrastructure runs on.

Practical consequences:

• Apply early. The registration is administrative but not instant, and nothing downstream can start without it.
• One PZN per pack variant. A second pack size is a second registration and a second listing conversation.
• Get the master data right at registration. Correcting an attribute after distribution has started propagates slowly through every downstream system and looks, to a buyer, like an operational warning sign.

Timing

Once regulatory clearance and master data exist, listing cycles typically run one to two quarters, driven by the wholesaler’s and chain’s range-review calendars rather than by your readiness. Missing a review window costs a quarter regardless of how complete your submission is.

Working backwards from a launch date: registration and master data first, then the commercial case, then the range-review submission, then launch support. Compressing that sequence tends to produce a listing without support, which is the worst of both outcomes.

After the listing: the part that is usually unowned

A listing is permission to be ordered, not a guarantee of sales. Products stall in a predictable way — listed, stocked once, never reordered — because nobody owned the follow-through: pharmacy-facing material within the permitted claim framework, staff briefing, and a check on actual rotation against the plan at the first review.

The range review that removed the product will not explain itself. It simply arrives.

A product that is listed but not rotating has a commercial problem, not a regulatory one — and it is the cheaper of the two to fix, if someone is watching.

---

We build the commercial case in the terms buyers use and execute the launch through the same network that carries our own brands — see commercialisation.